4 days ago
Novo Nordisk A/S (NYSE:NVO) shares are down during Wednesday’s premarket session. The down move comes as the company announced plans to cut the list prices of its GLP-1 drugs by up to 50% in the U.S. starting in 2027, adding pressure as broader markets edged lower.
Novo Nordisk Announces Major GLP-1 Drug Price Cuts
The price reduction, announced on Tuesday, will affect popular medications such as Wegovy, Ozempic, and Rybelsus, with the new list price set at $675 per month, down from current prices ranging from $1,027 to $1,350.
This move aims to alleviate out-of-pocket costs for patients, especially those enrolled in high-deductible plans, who often delay treatment due to high expenses.
In addition, the company’s CEO, Mike Doustdar, mentioned that Novo Nordisk aims to reach about 15 million new patients when Medicare begins ...
